
GNI Group Co., Ltd. has agreed to acquire all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. The transaction values Ayumi at approximately ¥44.8 billion. It will make Ayumi a wholly owned subsidiary of GNI Group upon completion.
Announced on June 7, 2026, the GNI Group Ayumi acquisition is intended to expand the company’s pharmaceutical business in Japan. GNI Group expects Ayumi’s established products and nationwide commercial network to support the introduction of innovative therapies and biosimilars. Furthermore, it believes these resources will help introduce internally developed medicines into the Japanese market.
Following the transaction, GNI Group expects combined fiscal 2026 revenue to reach approximately ¥65.2 billion. This figure is a company forecast rather than an achieved financial result.
Ayumi Brings Established Products and Commercial Capabilities
Ayumi Pharmaceutical has an established position in Japan’s pain management and rheumatology markets, alongside products used in orthopedic care. Its nationwide commercial network serves healthcare institutions across the country.
According to the announcement, Ayumi’s flagship product, Calonal®, an acetaminophen medicine, holds more than 80% of Japan’s domestic acetaminophen market.
For the fiscal year ended March 2026, Ayumi reported consolidated revenue of approximately ¥38.5 billion and operating profit of approximately ¥6.2 billion. The company also provides contract manufacturing services. In addition, it maintains manufacturing and commercial operations in Japan.
Acquisition Supports GNI Group’s Expansion in Japan
GNI Group expects Ayumi to provide a larger recurring revenue platform in Japan and create opportunities for pharmaceutical licensing and commercialization. Moreover, Ayumi’s products, customer relationships, and distribution capabilities are expected to complement GNI Group’s existing drug development activities.
The company identified several potential benefits from the transaction:
- Expanding its capabilities in pain management, rheumatology, and orthopedics.
- Supporting the introduction of overseas pharmaceuticals and biosimilars into Japan.
- Diversifying revenue across Japan, China, and the United States.
- Strengthening cash generation and financial stability.
- Creating opportunities for cross-selling and cooperation across the combined product portfolio.
GNI Group also expects the acquisition to expand its employee base, marketed products, and development pipeline. The combined business will focus on five therapeutic areas: fibrosis, pain management, rheumatology, oncology, and orthopedics.
Company Leaders Outline Growth Plans
Ying Luo, President and CEO of GNI Group, described the agreement as a milestone in the company’s strategy to build a cross-Pacific biopharmaceutical business. He said Ayumi’s commercial infrastructure and pain management portfolio would strengthen GNI Group’s ability to bring additional treatments to patients in Japan.
Luo also welcomed Blackstone, Toho, and Hisamitsu as new shareholders. He said the company looked forward to working with its stakeholders on the next phase of growth.
Atsuhiko Sakamoto, Head of Private Equity at Blackstone Japan, described Ayumi as Blackstone’s first controlling private equity investment in Japan. He said Blackstone had worked with Ayumi’s management to strengthen its business foundation, support growth, and establish its market position.
About GNI Group
GNI Group is a Japan-headquartered biopharmaceutical company with operations in Japan, China, the United States, and Australia. Its activities include drug discovery, pharmaceutical development and commercialization, and medical technology.
The company’s marketed products and development pipeline target fibrosis, cancer, inflammatory diseases, pain, and other serious conditions. GNI Group also holds a controlling interest in Gyre Therapeutics, Inc., a Nasdaq-listed U.S. biopharmaceutical company focused on fibrosis, inflammatory diseases, and cancer.

